Mazdutide in brief
Mazdutide is a synthetic 34-residue peptide built on the human oxyntomodulin sequence, with 2-aminoisobutyric acid at position 2, a C-terminal glycinamide and a C20 fatty diacid on Lys20; the whole conjugate is C210H322N46O67, about 4563 g/mol. Its registry identity is settled (CAS 2259884-03-0, UNII MB76Z4IBZ5), and the codes LY3305677 and IBI362 name the same molecule. It is described as an agonist at the human GLP-1 and glucagon receptors, but the measured receptor data come almost entirely from the originating patent. No experimental or computed 3D structure exists, and PubChem's record is one serine shorter than the registered sequence.[1,2,3,4,5,6]
Mazdutide regulatory status
No marketing authorisation as a medicine was found for mazdutide in Drugs@FDA, the EMA medicines data or the Health Canada Drug Product Database (searched November 2026). A publisher profile of its development records a first approval in China in June 2025, for long-term body weight management in adults with obesity or overweight, and a second approval there in September 2025 for glycaemic control in adults with type 2 diabetes. Phase 3 trials registered on ClinicalTrials.gov and recorded as completed cover obesity or overweight (NCT05607680) and type 2 diabetes (NCT05606913). Neither the name mazdutide nor either development code appears on the WADA 2026 Prohibited List, which names substance classes rather than every substance, and whose S0 class reaches any pharmacological substance with no current approval by a governmental health authority for human therapeutic use. It appears nowhere on the FDA's list of bulk drug substances that may present significant safety risks, in neither the category 2 table nor the table of nominations withdrawn by their nominators (page content current as of 22 April 2026), and no nomination for it was found there. No retraction or expression of concern is recorded against any source cited on this page.[7,8,9,10,11,12,13,14]
Mazdutide at a glance
- A 34-residue linear peptide with three departures from ordinary protein chemistry: 2-aminoisobutyric acid at position 2, a C-terminal glycinamide, and a C20 fatty diacid attached to the Lys20 side chain through a gamma-linked glutamate and two AEEA spacers. The whole conjugate is C210H322N46O67, about 4563 g/mol.[1,2,4]
- Registry identity is settled: CAS 2259884-03-0, UNII MB76Z4IBZ5, INN list number 12034, KEGG D12225. The development codes LY3305677 and IBI362 name the same molecule and run through the earlier literature.[1,2,3]
- The sequence is a modified human oxyntomodulin, not a GLP-1 or GIP analogue, which is what distinguishes this molecule from the other lipidated incretin-receptor peptides it is usually listed beside.[5,15,16]
- Measured receptor-level data come almost entirely from the originating patent: at human receptors expressed in HEK293 cells the matching compound showed inhibition constants of 28.6 nM at the GLP-1 receptor and 17.7 nM at the glucagon receptor, with cAMP half-maximal concentrations of 83.1 nM and 26.5 nM respectively, both two to three orders of magnitude weaker than the native hormone at its own receptor.[4]
- No experimental structure exists. The peptide is in no Protein Data Bank entry, and no computed conformer is published, so nothing here shows how it sits in either receptor pocket.[17,6]
What is Mazdutide?
Mazdutide is a synthetic peptide derived from the sequence of human oxyntomodulin, a 37-residue product of the proglucagon gene (residues 53 to 89 of pro-glucagon) whose first 29 residues are glucagon itself. Oxyntomodulin is of interest because one molecule engages two receptors, the glucagon receptor and the GLP-1 receptor, both class B1 G protein-coupled receptors. The peptide was first described in a 2015 patent application from Eli Lilly and Company, which claims a family of glucagon and GLP-1 co-agonist compounds built on this backbone; the molecule was subsequently developed by Innovent Biologics as IBI362 and carried the Lilly code LY3305677 in parallel.[5,4,18,10]
Chemically it belongs to the same class as several other long-acting peptides: a backbone stabilised against aminopeptidase cleavage by an alpha,alpha-dialkyl residue at position 2, amidated at the C-terminus, and carrying a fatty-diacid arm on a lysine side chain. The papers describing it call it a long-acting synthetic analogue of mammalian oxyntomodulin with a fatty-acyl moiety attached. What distinguishes it from the names it is listed beside is the backbone rather than the lipid: GLP-1 SM is built on GLP-1, GLP-2 TZ on GIP, and mazdutide on oxyntomodulin.[3,15,19,16]
The design question the molecule sits inside is a conflict between its two arms. Glucagon-receptor agonism raises blood glucose, which is the opposite of what GLP-1 receptor agonism does, and the 2024 phase 2 report states plainly that this was long held to be the obstacle to developing agonists of both receptors in one molecule. Two reviews put the same point in terms of relative potency: the ratio of activity at the two receptors is what differentiates one dual agonist from another, and the mechanistic evidence for what glucagon-receptor agonism does during chronic exposure comes almost entirely from rodent models rather than from human measurement.[16,20,21,22]
Its development status is split by jurisdiction, and that is worth stating plainly because almost every source on this page was written at a different point in it. A publisher profile of the compound records a first regulatory approval in China in June 2025 and a second Chinese approval in September 2025, each naming an indication; no authorisation was found in the United States, the European Union or Canada when the three agency databases were queried for this page, and the registered phase 3 programme is recorded on ClinicalTrials.gov as completed. So the molecule is an approved medicine in one country and an investigational one elsewhere, and the material sold under this name outside a pharmaceutical supply chain is neither.[10,7,8,9,11,12]
Beyond the registered name, a label is a claim. Nothing in the public record ties any particular preparation to the registered structure, and the published analytical work shows that telling these closely related peptides apart takes accurate-mass measurement with fragment confirmation.[1,23]
Not to be confused with
- Oxyntomodulin
- The endogenous 37-residue proglucagon product, residues 53 to 89 of human pro-glucagon. Mazdutide is not oxyntomodulin: aligned position by position against it, the peptide carries 2-aminoisobutyric acid where oxyntomodulin has Ser2, eight further residue substitutions between positions 16 and 28, a different C-terminal segment (GGPSSG in place of oxyntomodulin's TKRNRNNIA tail after position 28), a C-terminal amide instead of a free acid, and a lipid arm on Lys20 that the hormone does not have.[5,1,4]
- GLP-1 SM
- An agonist at the GLP-1 receptor only, built on the GLP-1 backbone rather than the oxyntomodulin backbone. The two were compared directly in a cell assay at the rat GLP-1 receptor and in a mouse imaging study, and they are chemically separate peptides.[4,27]
- GLP-2 TZ
- A dual GIP and GLP-1 receptor agonist developed from the GIP backbone. It carries no glucagon receptor arm, which is the arm mazdutide is characterised by, and a validated chromatographic method identifies the two as separate species by accurate mass with fragment confirmation.[23,21]
- GLP-3 RT and survodutide
- Other multi-receptor peptides in the same literature. GLP-3 RT adds a deliberate GIP receptor arm to the GLP-1 and glucagon pair; survodutide is a separate GLP-1 and glucagon receptor dual agonist with its own sequence and its own reported potency balance at the two receptors. Both appear beside mazdutide in the nine-agonist analytical panel as distinct molecules.[23,22]
- Exendin-4
- A 39-residue lizard peptide. Mazdutide's C-terminal GGPSSG hexapeptide also occurs within exendin-4's C-terminal region and is absent from human oxyntomodulin, which is a sequence coincidence worth naming; nothing read here states that mazdutide's tail was taken from exendin-4, and the two peptides are otherwise unrelated in sequence.[24,5]
Mazdutide structure and sequence
The verified chain is His-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Lys-Ala-Lys-Glu-Phe-Val-Glu-Trp-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly, amidated at the C-terminal glycine, with the Lys at position 20 bearing the lipid arm. Two independent registries agree on it: the FDA substance record gives the subunit, the three structural modifications and the full systematic name, and KEGG gives the same 34-residue sequence together with the formula C210H322N46O67 and an exact mass of 4560.3203 Da. Rebuilding the molecule residue by residue from that sequence, with one Aib methyl group, a C-terminal amide, two AEEA units, one gamma-glutamate and a C20 diacid, reproduces that formula exactly, which is the arithmetic check that ties the written structure to the published mass.[1,2]
Set against human oxyntomodulin, the changes are easy to read off. Position 2 becomes Aib. Positions 16, 17, 18, 20, 21, 24, 27 and 28 are substituted, and one of those substitutions is the point of attachment: oxyntomodulin's Gln20 becomes the lysine that carries the lipid. After position 28 the two sequences part company altogether: oxyntomodulin continues with a basic TKRNRNNIA tail, while mazdutide ends GGPSSG, a hexapeptide that also occurs in exendin-4 and not in any human proglucagon product. The lipid arm itself is the same architectural idea used in other long-acting peptides, a fatty diacid held away from the backbone by a glutamate and a short polyethylene-glycol-like spacer, with the distal carboxylate left free.[5,24,1,4]
The patent is what makes the attachment chemistry checkable. Its Example 1 series walks through four compounds differing only in diacid length and spacer count, each with a calculated and an observed deconvoluted mass; the one carrying two AEEA units, one gamma-glutamate and eicosanedioic acid is reported at 4563.1 calculated against 4562.9 observed, which matches the registered composition and the KEGG mass. There is no three-dimensional view to accompany any of this: the peptide appears in no Protein Data Bank entry, the nearest sequence neighbours there are a different molecule, and no computed conformer is published.[4,2,17,6]
Modifications
- 2 2-aminoisobutyric acid (Aib, alpha-methylalanine), an achiral alpha,alpha-dialkyl residue in place of the serine that occupies this position in human oxyntomodulin.[1,2,5]
- 20 The lysine side-chain (epsilon) nitrogen carries two [2-(2-aminoethoxy)ethoxy]acetyl (AEEA) spacer units joined to a single gamma-linked L-glutamate, which in turn bears eicosanedioic acid, a C20 alpha,omega-dicarboxylic acid. The distal carboxylate of the diacid is free. The registry names the whole group N6-(N-(hydrogen icosanedioyl)-gamma-Glu-bis(iminobis(ethylenoxy)acetyl))-lysine; the patent writes the same arm as ([2-(2-aminoethoxy)ethoxy]acetyl)2-(gamma-Glu)1-CO-(CH2)18-CO2H.[1,4]
- 34 C-terminal glycinamide rather than a free carboxylate.[1,4]
The backbone is all-L apart from the four glycines and the Aib residue at position 2, which is achiral, and the linker glutamate is the L enantiomer, gamma-linked. There are no cysteines, so there is no disulfide; the peptide is linear and uncyclised, with no glycosylation and no metal coordination. The only branch point is the Lys20 side-chain nitrogen bearing the two AEEA spacers, the gamma-glutamate and the C20 diacid.[1,4]
What studies on Mazdutide show
Each card names the experimental system and what was measured. A result in one system is not evidence about another.
Radioligand binding and cAMP accumulation assays, reported in the originating patent · Crude plasma membranes from HEK293 cells overexpressing the cloned human GLP-1 receptor or human glucagon receptor for binding; HEK293 clonal lines overexpressing each receptor for cAMP, in medium containing 0.05% bovine albumin and 0.25% dialysed serum as assay conditions; rat INS1 832-3 insulinoma cells for the endogenous rat GLP-1 receptor; primary human hepatocytes for the endogenous human glucagon receptor
At the human GLP-1 receptor Ki was 28.6 +/- 4.8 nM (n = 4) against 0.75 nM for GLP-1(7-36)NH2; at the human glucagon receptor Ki was 17.7 +/- 5.0 nM (n = 4) against 2.49 nM for glucagon. For cAMP, EC50 was 83.1 +/- 16.8 nM at the GLP-1 receptor and 26.5 +/- 2.2 nM at the glucagon receptor, with Emax of 107% and 114% of the native hormone's maximum; wild-type oxyntomodulin gave 9.54 nM and 0.757 nM in the same assays. In rat INS1 832-3 cells the EC50 was 62 nM against 5.8 nM for GLP-1 SM, and in primary human hepatocytes 159.4 nM against 29.8 nM for oxyntomodulin.[4]
- Material
- Compound 2 of the patent, the 34-residue Aib2 peptide with the C-terminal amide and the (AEEA)2-gamma-Glu-C20 diacid arm on Lys20, whose calculated and observed masses match the registered mazdutide composition
- Measured
- Inhibition constants (Ki) at each human receptor, and half-maximal effective concentration (EC50) with maximal effect (Emax) for cAMP accumulation
- Compared with
- Human glucagon, human GLP-1(7-36)NH2, wild-type human oxyntomodulin, GLP-1 SM, and three sibling compounds differing in diacid length and spacer count
- Limitation
- Patent data, generated by the sponsor and not peer reviewed; the patent does not use the name mazdutide, so the correspondence rests on matching composition and mass rather than a stated equivalence. The hepatocyte and INS1 readings are single determinations. Every functional measure is cAMP accumulation, so nothing is established about arrestin recruitment, receptor internalisation or pathway bias, and the recombinant overexpression systems do not report receptor-reserve effects.
Mezo AR et al., 2018, United States Patent and Trademark Office
Liquid chromatography with high-resolution mass spectrometry, method validation · Reference standards of nine peptide GLP-1 receptor agonists on a C18 column with difluoroacetic acid and dimethyl sulfoxide additives, plus three marketed formulations analysed by dilute-and-shoot
Top-down identification achieved mass accuracy of 0.0 to 0.5 ppm with fragment-ion coverage of 76 to 100% across the panel, with baseline separation for most of the nine inside a 20-minute run and linearity from 4 to 235 ng/mL. Single, dual and triple receptor agonists of closely related sequence are therefore separable and individually identifiable by accurate mass with fragment confirmation.[23]
- Material
- Mazdutide as one of nine standards, beside bofanglutide, ecnoglutide, exenatide, GLP-1 LR, GLP-3 RT, GLP-1 SM, survodutide and GLP-2 TZ
- Measured
- Chromatographic resolution, mass accuracy, fragment-ion coverage, linearity, limits of detection and quantitation
- Compared with
- The other eight peptides in the same run
- Limitation
- Read as abstract only, so the per-peptide figures for this molecule were not verified at source. The abstract reports baseline separation for most peptides rather than all nine. The application samples were formulations of three other peptides, so no mazdutide preparation was actually analysed, and the method establishes identifiability rather than the identity of any particular material.
Tong LH et al., 2026, Journal of Chromatography A
Mouse model with a parallel cell experiment, western blot and immunohistochemistry readouts · Male C57BL/6J mice on a 12-week high-fat diet, then four weeks of treatment; separately, the AML-12 mouse hepatocyte line loaded with 1 mM free fatty acids (oleic and palmitic acid, 2:1) for 24 h
In the diet-fed mice the treated groups differed from the untreated model group on the liver-to-body-weight ratio, lipid and oxidative-stress measures and histological steatosis. In the loaded hepatocytes, intracellular triglyceride fell across assay concentrations of 5 to 200 nM, with the largest differences at 10 to 50 nM, and the same PERK-pathway, NF-kB and lipogenic-regulator protein levels moved in both systems.[25]
- Material
- Mazdutide acetate obtained from a commercial reagent vendor, with no identity or purity verification reported
- Measured
- Liver-to-body-weight ratio, serum and hepatic lipid measures, malondialdehyde and superoxide dismutase, histological steatosis, intracellular triglyceride, and protein levels of GRP78, ATF4, CHOP, phospho-PERK, phospho-eIF2alpha, NF-kB p65, TNF-alpha, SREBP-1, C/EBPbeta and PPARgamma
- Compared with
- Untreated diet model groups, normal-chow controls, and the endoplasmic reticulum stress inhibitor 4-phenylbutyric acid in the cell experiment
- Limitation
- No receptor antagonist, knockdown or receptor-null control is used, so none of these changes is attributed to either receptor by experiment; the pathway claim is an association between treatment and protein levels. The material is reagent-vendor supplied with no reported identity check. One laboratory, one sex, one diet model, and the figures are relative protein and lipid measures rather than receptor-level quantities.
Gan L et al., 2026, Pharmaceuticals
Rodent study with behavioural testing and transcriptomic, proteomic and metabolomic profiling · Male db/db mice, a leptin-receptor-deficient model, over 12 weeks
Food and water intake fell with increasing amounts relative to saline. Behavioural and histological measures differed from saline, and at the highest level studied from GLP-1 DG as well; the brain transcriptomic, proteomic and metabolomic profiles separated from the GLP-1 DG profiles rather than overlapping them, which the authors read as a contribution from the glucagon receptor arm.[26]
- Material
- Mazdutide (IBI362) supplied by Innovent Biologics
- Measured
- Food and water intake, body weight, behavioural test performance including Y-maze spontaneous alternation, brain histology, and multi-omics profiles including the glutamate transporter VGlut2
- Compared with
- Saline, and GLP-1 DG as a GLP-1 receptor agonist control
- Limitation
- Male mice only, which the paper states explicitly. The behavioural readouts are confounded by the large accompanying differences in intake and body weight, so they cannot separate a direct effect in brain tissue from a consequence of altered metabolism. No antagonist or receptor-knockout arm tests the attribution to the glucagon receptor, and the omics separation is correlative.
Dong W et al., 2025, EBioMedicine
Quantitative imaging in a rodent model with histological correlation · 42 male mice fed a high-fat diet for 13 weeks, then treated for four weeks; 9.4-T magnetic resonance imaging with 14 age-matched chow-fed controls
At 4 weeks the dual-agonist group's change in proton density fat fraction from baseline differed from the monoagonist group's (median -5.59% against -3.30%, P = .02); at 1 week there was no evidence of a difference, and the iron measure did not differ at either time. The imaging measure correlated with hepatic triglyceride (r = 0.82) and histological steatosis (r = 0.81).[27]
- Material
- Mazdutide as the dual-agonist arm
- Measured
- Proton density fat fraction (hepatic fat) and R2* (hepatic iron) at baseline, 1 week and 4 weeks, with hepatic triglyceride and histological steatosis scores for correlation
- Compared with
- GLP-1 SM as a GLP-1 receptor monoagonist arm, and phosphate-buffered saline
- Limitation
- Read as abstract only. One strain and one sex. The two peptides have different potencies at their shared receptor, so a between-compound difference at a chosen amount cannot be read as a difference between one-receptor and two-receptor engagement. The endpoints are an imaging surrogate and its histological correlate in a diet model.
Xia H et al., 2025, Radiology
Pharmacokinetic measurement within early-phase clinical studies · Adults in phase 1b studies in China, with plasma concentrations measured by immunoassay or mass spectrometry and analysed by non-compartmental methods
Absorption was slow, with a median time to peak concentration near 72 hours, and plasma concentrations then declined over weeks: reported terminal half-life ranges were 150.9 to 403.5 hours in the first cohort set, 147.3 to 673.3 hours in the type 2 diabetes study and 174.8 to 1075.7 hours in the higher-amount cohorts. Anti-drug antibodies were detected in a minority of participants, with no neutralising antibodies reported.[3]
- Material
- IBI362, later named mazdutide
- Measured
- Time to peak plasma concentration, terminal elimination half-life, area under the concentration-time curve, and anti-drug antibody status
- Compared with
- Placebo for safety and tolerability; no active comparator for the kinetics
- Limitation
- These are the kinetics of the formulated material in small cohorts, not a property of the molecule measured in a controlled system, and the reported half-life ranges are very wide and inconsistent between studies without explanation. All the studies are sponsor-funded with sponsor employees among the authors. The figures support nothing about receptor behaviour, and the lipid arm's contribution to the long residence time is an inference from the molecule's design rather than something these studies tested.
Ji L et al., 2021, EClinicalMedicine
What has been measured at the GLP-1 and glucagon receptors, and what has not
The receptor-level account of this peptide rests on one body of work, the originating patent, and it is narrower than the literature around it suggests. In cells overexpressing the human receptors the compound bound both with inhibition constants in the tens of nanomolar and raised cAMP at both, with a maximal effect at or slightly above the native hormone's, which is what agonism at both receptors means here. In those same assays its half-maximal concentrations were roughly 500-fold weaker than GLP-1 at the GLP-1 receptor, roughly 1000-fold weaker than glucagon at the glucagon receptor, and around 9-fold and 35-fold weaker than oxyntomodulin itself. Assay medium contained bovine albumin, and a lipidated peptide binds albumin, so a potency measured under those conditions is not directly comparable to an unmodified hormone's.[4]
Every functional number is cAMP accumulation. No arrestin recruitment, internalisation, trafficking or bias measurement for this peptide was located, and no structure of it bound to either receptor exists, so there is no description of which receptor residues it contacts or how its two activities are encoded in the sequence. The reviews that discuss the compound class make the same point from the other direction: the balance of potency between the two receptors is what distinguishes these molecules from each other, and for this one that balance has been reported once, by its originator, in a recombinant system.[4,22,20]
Below the receptor, what is published is organism-level. The rodent studies measured hepatic lipid and oxidative-stress markers, protein levels in stress and lipogenesis pathways, intake, imaging fat fraction and behavioural performance in named strains, and none of them included a receptor antagonist or a receptor-null arm, so none of them attributes its measurements to either receptor by experiment. Two reviews state that the mechanistic evidence for chronic glucagon-receptor agonism is drawn from rodent models and that the pathways engaged in humans remain undelineated.[25,26,27,20,21]

What is still unknown about Mazdutide
The most concrete identity problem is a public record that disagrees with itself. The FDA substance registry and KEGG both give a 34-residue chain ending Pro-Ser-Ser-Gly-amide, and KEGG's formula and exact mass are reproduced exactly by rebuilding that structure from its parts; the ChemSpider record agrees, giving the same formula C210H322N46O67 and the same monoisotopic mass. PubChem's record for the same name carries a structure one serine shorter, ending Pro-Ser-Gly-amide, with a formula and masses that are self-consistent for that shorter molecule and roughly 87 Da below the registered one. Anyone copying a formula or a mass from the PubChem record is describing a different peptide. A second, smaller conflict sits inside the registry itself: one of its alternative systematic names describes a single AEEA spacer where the primary name and the structural modification both specify two.[6,1,2,28]
Readers will also meet this peptide described as 33 residues rather than 34, and that turns out to be two different things wearing one number. On the catalogue page checked here the count is a naming convention: its formal name spells out 33 amino acyl residues and then a C-terminal glycinamide, and the molecular formula and formula weight it publishes, C210H322N46O67 and 4563.1, are the registered molecule's, so nothing is missing. The PubChem record is the other case, and there a residue really is absent. A 33-residue description is therefore not evidence of an error by itself; the formula and the mass are what separate the two readings.[29,6,1,2]
The receptor data have a single origin and a thin provenance. The 2021 and 2022 clinical reports state that the peptide bound human and mouse GLP-1 and glucagon receptors in vitro, but they cite two conference abstracts for it rather than a paper, and those abstracts were not retrievable here. So the only numerical receptor measurements on this page come from the patent, which does not use the name mazdutide; the link between its Compound 2 and the registered molecule is an inference from identical composition and matching calculated and observed mass, strong but not stated by any source. The one public record that does connect the two points at the wrong compound: PubChem carries the synonym "compound 1 [US9938335B2]", but the patent's Compound 1 is built with octadecanedioic acid and is reported at 4535.0 calculated, while the registries specify an icosanedioyl (C20) arm and a mass near 4563, which is Compound 2. No independently curated affinity table was consulted: the IUPHAR/BPS record that PubChem's synonym points to requires an API key, and the ChEMBL record carried no bioactivity data when read.[3,30,4,31,6]
There is no structural information at all, and that gap is the largest one. The absence has been checked rather than assumed: full-text searches of the Protein Data Bank find nothing, and a sequence search returns only entries containing a different peptide whose sequence diverges from position 16 onward. Nothing therefore describes this peptide's conformation when bound, which residues reach into either receptor pocket, or where the lipid arm sits. The same absence applies to the question of how the two activities are balanced at the molecular level, which the cardiovascular review names as the property that differentiates one dual agonist from another.[17,6,22]
The preclinical literature is thin in a particular way: almost entirely organism-level, single-laboratory and single-sex, with no receptor-selective controls, and the material's provenance varies between sponsor-supplied and reagent-vendor supplied with no reported identity check in either case. Two independent rodent reports do agree that hepatic fat measures moved in diet-fed mice, which is a modest replication, but neither establishes a receptor mechanism. Against this the clinical record is large and recent, with phase 1, 2 and 3 studies run in China by Innovent Biologics and in the United States by Eli Lilly, and a 2025 publisher profile recording a first regulatory approval in China in June 2025. Those are bibliographic facts about the compound's development rather than receptor-level characterisation, and their endpoints are outside what this page reports.[25,27,26,32,33,34,35,36,10,18]
One claim about the preclinical record could not be traced to a source. Catalogue descriptions of this peptide state that it reduces body weight in both glucagon-receptor-null and GLP-1-receptor-null mice, which would be exactly the receptor-selective control this page says the published work lacks. The page checked here cites the 2021 phase 1b report for it; the full text of that report, and of the 2022 phase 1b report beside it, contain no mention of a knockout, of Gcgr or of Glp1r, and a PubMed search returning 58 records for the name and both development codes surfaced no study with a receptor-null arm. So the statement in the mechanism section stands as written: no receptor-selective control has been located in the literature read here.[29,3,30]
Key papers on Mazdutide
- Glucagon and GLP-1 co-agonist compounds. United States patent US 9,938,335 B2.
Mezo AR, Chen Y, Valenzuela FA, Qu H (inventors); Eli Lilly and Company (assignee) (2018), United States Patent and Trademark Office · Patent with receptor binding, cAMP assays and mass characterisation
The originating patent, and the only source read here with measured binding and cAMP numbers at both human receptors, alongside the synthesis and the mass confirmation that pin the structure down.
- MAZDUTIDE: substance record, unique ingredient identifier MB76Z4IBZ5.
FDA Global Substance Registration System (2026), FDA Global Substance Registration System · Regulatory substance record
The authoritative identity record: the 34-residue subunit, the three structural modifications spelled out, and the registry codes. Read it beside the KEGG entry rather than beside PubChem's.
- KEGG DRUG entry D12225: Mazdutide (USAN/INN).
Kanehisa Laboratories (2026), KEGG DRUG · Curated drug database record
The published formula and exact mass for the whole conjugate, which is the figure to check any other mass against.
- IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.
Ji L, Jiang H, An P, Deng H, Liu M, Li L, Feng L, Song B, Han-Zhang H, Ma Q, Qian L (2021), EClinicalMedicine · Phase 1b study, open access
The first clinical report, which is where the description of the molecule as a lipidated oxyntomodulin analogue and the citation trail to the unpublished in vitro work both start.
- Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Tong LH, Leung KK, Hung CT (2026), Journal of Chromatography A · Analytical method validation
Shows what it takes to tell this peptide apart from eight closely related ones: accurate mass with fragment confirmation, not a name.
- IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.
Elmendorf AJ, Yousefian M, Kim IM, Hardaway JA, Habegger K, Flak JN (2026), Pharmacological Research · Review of glucagon receptor pharmacology
The best statement of how little is known about chronic glucagon-receptor agonism in humans, which is the half of this molecule with the least evidence behind it.
- Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.
Gan L, Duan L, Zheng X (2026), Pharmaceuticals · Rodent and cell study, open access
A representative preclinical study, worth reading for its limits as much as its results: detailed pathway readouts with no receptor-selective control anywhere in the design.
References
- 1.FDA Global Substance Registration System. (2026). MAZDUTIDE: substance record, unique ingredient identifier MB76Z4IBZ5. FDA Global Substance Registration System. source · database record
- 2.Kanehisa Laboratories. (2026). KEGG DRUG entry D12225: Mazdutide (USAN/INN). KEGG DRUG. source · database record
- 3.Ji L, Jiang H, An P, Deng H, Liu M, Li L, Feng L, Song B, Han-Zhang H, Ma Q, Qian L. (2021). IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine. 39:101088. doi:10.1016/j.eclinm.2021.101088 · full text read
- 4.Mezo AR, Chen Y, Valenzuela FA, Qu H (inventors); Eli Lilly and Company (assignee). (2018). Glucagon and GLP-1 co-agonist compounds. United States patent US 9,938,335 B2. United States Patent and Trademark Office. source · full text read
- 5.UniProt Consortium. (2026). UniProtKB P01275 (GLUC_HUMAN): Pro-glucagon, Homo sapiens. UniProtKB. source · database record
- 6.National Center for Biotechnology Information. (2026). PubChem Compound Summary for CID 167312357, Mazdutide. PubChem. source · database record
- 7.U.S. Food and Drug Administration. (2026). Drugs@FDA data via the openFDA drugsfda endpoint: active-ingredient and generic-name query for "mazdutide", no matching application returned (queried November 2026). openFDA. source · database record
- 8.European Medicines Agency. (2026). Medicines output: medicines, the agency's JSON data report of centrally evaluated human and veterinary medicines (queried November 2026). European Medicines Agency. source · database record
- 9.Health Canada. (2026). Drug Product Database active-ingredient query for "mazdutide", no matching product returned (queried November 2026). Drug Product Database. source · database record
- 10.Shirley M. (2025). Mazdutide: First Approval. Drugs. 85:1621-1627. doi:10.1007/s40265-025-02249-y · abstract only
- 11.ClinicalTrials.gov (U.S. National Library of Medicine). (2026). A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants With Obesity or Overweight (GLORY-1) (NCT05607680). ClinicalTrials.gov. source · database record
- 12.ClinicalTrials.gov (U.S. National Library of Medicine). (2026). Efficacy and Safety of IBI362 Versus [GLP-1 DG] as add-on to Metformin and/or SGLT2 Inhibitor or TZD in Subjects With Type 2 Diabetes (DREAMS-2) (NCT05606913). ClinicalTrials.gov. source · database record
- 13.World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026. World Anti-Doping Agency. source · full text read
- 14.U.S. Food and Drug Administration. (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (category 2 of the substances nominated under sections 503A or 503B, and the table of nominations withdrawn by their nominators), content current as of 04/22/2026. U.S. Food and Drug Administration. source · full text read
- 15.Ji L, Gao L, Jiang H, Yang J, Yu L, Wen J, Cai C, Deng H, Feng L, Song B, Ma Q, Qian L. (2022). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine. 54:101691. doi:10.1016/j.eclinm.2022.101691 · full text read
- 16.Zhang B, Cheng Z, Chen J, Zhang X, Liu D, Jiang H, Ma G, Wang X, Gan S, Sun J, Jin P, Yi J, Shi B, Ma J, Ye S, Wang G, Ji L, Gu X, Yu T, An P, Deng H, Li H, Li L, Ma Q, Qian L, Yang W. (2024). Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes Care. 47:160-168. doi:10.2337/dc23-1287 · full text read
- 17.Research Collaboratory for Structural Bioinformatics. (2026). RCSB PDB sequence and full-text searches for mazdutide, IBI362 and LY3305677. RCSB Protein Data Bank. source · database record
- 18.Abdul Fasi M. (2026). Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes. Expert Opinion on Therapeutic Patents. 36:459-469. doi:10.1080/13543776.2026.2645812 · abstract only
- 19.Ji L, Jiang H, Cheng Z, Qiu W, Liao L, Zhang Y, Li X, Pang S, Zhang L, Chen L, Yang T, Li Y, Qu S, Wen J, Gu J, Deng H, Wang Y, Li L, Han-Zhang H, Ma Q, Qian L. (2023). A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature Communications. 14:8289. doi:10.1038/s41467-023-44067-4 · full text read
- 20.Elmendorf AJ, Yousefian M, Kim IM, Hardaway JA, Habegger K, Flak JN. (2026). IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes. Pharmacological Research. 223:108077. doi:10.1016/j.phrs.2025.108077 · abstract only
- 21.Neff GW. (2025). Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions. Diabetes, Obesity and Metabolism. 27:6869-6883. doi:10.1111/dom.70148 · abstract only
- 22.Kushner PR, Michos ED. (2026). Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus. Journal of the American Heart Association. 15:e049727. doi:10.1161/JAHA.126.049727 · abstract only
- 23.Tong LH, Leung KK, Hung CT. (2026). Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application. Journal of Chromatography A. 1786:467288. doi:10.1016/j.chroma.2026.467288 · abstract only
- 24.UniProt Consortium. (2026). UniProtKB P26349 (EXE4_HELSU): Exendin-4, Heloderma suspectum. UniProtKB. source · database record
- 25.Gan L, Duan L, Zheng X. (2026). Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation. Pharmaceuticals. 19:371. doi:10.3390/ph19030371 · full text read
- 26.Dong W, Bai J, Yuan Q, Zhang Y, Zhang Y, Zhang Z, Yang M, Li H, Zhao Z, Jiang H. (2025). Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis. EBioMedicine. 117:105791. doi:10.1016/j.ebiom.2025.105791 · full text read
- 27.Xia H, Min Y, Wang Y, Gao S, Wang H, Yan F, Liu R, Wang J, Gu X, Bo T. (2025). Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet-induced Mouse Model. Radiology. 316:e243780. doi:10.1148/radiol.243780 · abstract only
- 28.Royal Society of Chemistry. (2026). ChemSpider record 129341158: Mazdutide. ChemSpider. source · database record
- 29.Cayman Chemical. (2026). Mazdutide, catalogue item 40971: product description, formal name, molecular formula and formula weight. Cayman Chemical. source · full text read
- 30.Jiang H, Pang S, Zhang Y, Yu T, Liu M, Deng H, Li L, Feng L, Song B, Han-Zhang H, Ma Q, Qian L, Yang W. (2022). A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nature Communications. 13:3613. doi:10.1038/s41467-022-31328-x · full text read
- 31.European Bioinformatics Institute. (2026). ChEMBL molecule record CHEMBL5095358: MAZDUTIDE. ChEMBL. source · database record
- 32.Bhattachar SN, Tham LS, Li Y, Chua L, Ng SX, Tang Y, Ibriga H, Ni W, Gurbuz S, Mather KJ, Thomas MK. (2025). Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial. Diabetes, Obesity and Metabolism. 27:6460-6469. doi:10.1111/dom.70040 · full text read
- 33.Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, Zhao Y, Qiu W, Huang C, Chen L, Zhong S, Han J, Zhang Y, Lian Q, Yang P, Lv L, Gu J, Liu Z, Deng H, Wang Y, Li L, Pei L, Qian L; GLORY-1 Investigators. (2025). Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. New England Journal of Medicine. 392:2215-2225. doi:10.1056/NEJMoa2411528 · abstract only
- 34.Guo L, Zhang B, Xue X, Zhang X, Cai H, Jiang H, Zhang L, Jin P, Wang X, Cheng Z, Zhang S, Geng J, Guo Y, Hu H, Ma Q, Li L, Du H, Han-Zhang H, Xue F, Deng H, Qian L, Yang W; DREAMS-2 investigators. (2026). Mazdutide versus [GLP-1 DG] in Chinese adults with type 2 diabetes. Nature. 652:181-188. doi:10.1038/s41586-025-10031-z · abstract only
- 35.Zhu D, Zhao J, Cai H, Chu X, Xiu S, Song C, Cheng Z, Cao H, Jiang H, Zhang L, Wang H, Shi B, Li Y, Liu M, Feng B, Xue F, Deng H, Li H, Li L, Li Y, Ma Q, Qian L. (2026). Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 652:174-180. doi:10.1038/s41586-025-10026-w · abstract only
- 36.Hsia SH, Bays HE, Billings LK, Weideman AMK, Mather KJ, Coskun T, Haupt A, Thomas MK, Tham LS, Calderon B, Ni W, De Araujo OFG. (2026). Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. The Lancet Diabetes & Endocrinology. 14:879-893. doi:10.1016/S2213-8587(26)00160-9 · abstract only
Related entries
- GLP-1 SMGLP-1 SM is a long-acting synthetic GLP-1 receptor agonist, a 31-residue analogue of human glucagon-like peptide 1 with a fatty-acid side chain. That side chain binds serum albumin, and two backbone substitutions stiffen the cleavage site and leave the side chain only one place to attach.
- GLP-2 TZGLP-2 TZ is a synthetic 39-residue peptide carrying a twenty-carbon fatty-diacid side chain on Lys20. It activates two human class B1 G protein-coupled receptors, the GIP receptor and the GLP-1 receptor, with measurably different signalling behaviour at each.
- GLP-3 RTGLP-3 RT is an investigational synthetic 39-residue peptide from Eli Lilly, carrying a fatty-diacid side chain on Lys17. Within one molecule it activates three human class B1 G protein-coupled receptors, the GIP, GLP-1 and glucagon receptors.
- SurvodutideSurvodutide, development code BI 456906, is an investigational synthetic peptide built on the human glucagon sequence. It is characterised in the literature as an agonist at both the human glucagon and GLP-1 receptors, and carries a C18 fatty-diacid arm that binds albumin.
- CagrilintideCagrilintide is a long-acting synthetic analogue of the pancreatic hormone amylin: 37 residues carrying a C20 fatty diacid on the N-terminal lysine. It is investigational and approved nowhere.
